Biogen Idec Refocusing On U.S. Avonex Sales While Awaiting Tysabri's Fate

Multiple sclerosis product is up 10%, driven by European sales, but the U.S. market remains disappointing.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet